ELI Lilly has announced that The New England Journal of Medicine has published the results of the Phase 3 SURMOUNT-1 study, the longest study of the weight loss drug Mounjaro (tirzepatide) to date.
Over a 176-week treatment period, tirzepatide significantly reduced the risk of developing type 2 diabetes in adults with prediabetes and obesity or who are overweight, achieving notable weight loss.
On average, participants lost 22.9% of body weight, with nearly 99% remaining diabetes-free.
Tori Brown, Eli Lilly General Manager for ANZ, underscored the need for equitable access to Mounjaro, calling for a shift in PBS reimbursement priorities to ensure Australians with medical needs receive necessary care.
Lilly plans to submit the study's findings to the TGA.
The above article was sent to subscribers in Pharmacy Daily's issue from 15 Nov 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Nov 24
